Saturna Capital Corp Sells 21,067 Shares of Novo Nordisk A/S $NVO

Saturna Capital Corp cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.0% during the second quarter, HoldingsChannel.com reports. The fund owned 2,123,692 shares of the company’s stock after selling 21,067 shares during the quarter. Novo Nordisk A/S makes up approximately 2.0% of Saturna Capital Corp’s investment portfolio, making the stock its 17th biggest holding. Saturna Capital Corp’s holdings in Novo Nordisk A/S were worth $146,577,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of NVO. Jennison Associates LLC increased its holdings in Novo Nordisk A/S by 0.3% during the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after purchasing an additional 63,341 shares during the period. Kingstone Capital Partners Texas LLC lifted its stake in Novo Nordisk A/S by 301,443.6% in the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after acquiring an additional 10,001,898 shares during the period. Sustainable Growth Advisers LP grew its holdings in Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after acquiring an additional 649,390 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Novo Nordisk A/S by 11.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,692,554 shares of the company’s stock valued at $395,291,000 after purchasing an additional 576,900 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $370,272,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NVO opened at $47.56 on Wednesday. The company has a market cap of $212.34 billion, a P/E ratio of 13.07, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm’s 50-day moving average price is $54.30 and its 200-day moving average price is $60.70. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.74 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NVO has been the subject of a number of recent research reports. Hsbc Global Res raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. UBS Group cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Rothschild Redb upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. Finally, BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price for the company in a research note on Wednesday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.